Tasuku Honjo

Tasuku Honjo, born on January 27, 1942, is a distinguished Japanese immunologist whose groundbreaking research has significantly impacted cancer therapy. Honjo's academic journey culminated in a medical degree from Kyoto University in 1966 and a Ph.D. in medical chemistry from the same institution in 1975. His early career involved research fellowships at the Carnegie Institution for Science in Baltimore and the National Institutes of Health in Bethesda, Maryland, before returning to Japan to continue his work. His career highlights include the discovery of programmed cell death protein 1 (PD-1), a crucial regulator of the immune system. This discovery paved the way for the development of immune checkpoint inhibitors, a revolutionary class of cancer drugs that unleash the body's own immune system to fight tumors. Honjo's work has been recognized with numerous awards, most notably the 2018 Nobel Prize in Physiology or Medicine, which he shared with James P. Allison. His contributions have had a profound social and cultural impact, offering new hope to cancer patients worldwide. While Honjo's work is widely celebrated, the high cost and accessibility of immune checkpoint inhibitors have raised concerns. Nevertheless, his legacy as a pioneering immunologist is secure, and he is highly regarded by his peers and the broader scientific community for his dedication to advancing medical knowledge and improving human health. His standing among the people and his colleagues is undoubtedly one of high regard and respect.